Amneal Pharmaceuticals LLC

Contributing Author

Recent Articles by Amneal Pharmaceuticals LLC

12 hours	Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT for Parkinson's Disease, Including Over 3 More Hours of Daily "Good On" Time When Switching from RYTARY AMRX GlobeNewswire
Apr-14	Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S. AMRX GlobeNewswire
Apr-09	Amneal Launches Bimatoprost Ophthalmic Solution, 0.01% AMRX GlobeNewswire
Apr-07	Amneal to Report First Quarter 2026 Results on May 1, 2026 AMRX GlobeNewswire
Apr-07	Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson's Awareness Month AMRX GlobeNewswire
Mar-05	Amneal to Participate in Upcoming Investor Conference AMRX GlobeNewswire
Feb-27	Amneal Reports Fourth Quarter and Full Year 2025 Financial Results AMRX GlobeNewswire
Jan-28	Amneal Pharmaceuticals Added to S&P SmallCap 600 Index AMRX GlobeNewswire
Jan-27	Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026 AMRX GlobeNewswire
Dec-22	Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia and XGEVA AMRX GlobeNewswire
Dec-09	Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals AMRX GlobeNewswire
Dec-05	Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT for Parkinson's Disease AMRX GlobeNewswire
Dec-02	Amneal to Participate in Upcoming Investor Conferences AMRX GlobeNewswire
Dec-02	Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol AMRX GlobeNewswire
Dec-01	Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05% AMRX GlobeNewswire
Nov-13	Amneal Receives U.S. FDA Approval for Iohexol Injection AMRX GlobeNewswire
Oct-30	Amneal Reports Third Quarter 2025 Financial Results AMRX GlobeNewswire
Oct-29	Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol AMRX GlobeNewswire
Oct-27	Amneal Launches Brekiya - the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches AMRX GlobeNewswire
Sep-30	Amneal to Report Third Quarter 2025 Results on October 30, 2025 AMRX GlobeNewswire
Sep-26	Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR (omalizumab) AMRX GlobeNewswire
Sep-23	Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01% AMRX GlobeNewswire
Sep-11	Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution AMRX GlobeNewswire
Sep-04	Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension AMRX GlobeNewswire
Aug-05	Amneal Reports Second Quarter 2025 Financial Results AMRX GlobeNewswire
Jul-21	Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032 AMRX GlobeNewswire
Jul-21	Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results AMRX GlobeNewswire
Jul-09	Amneal to Report Second Quarter 2025 Results on August 5, 2025 AMRX GlobeNewswire
Jun-25	Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences AMRX GlobeNewswire
Jun-12	Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension AMRX GlobeNewswire
May-29	Amneal to Participate at Upcoming Investor Conferences in June AMRX GlobeNewswire
May-15	Amneal Receives U.S. FDA Approval for Brekiya (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults AMRX GlobeNewswire
May-08	Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S. AMRX GlobeNewswire

Amneal Pharmaceuticals LLC

Recent Articles by Amneal Pharmaceuticals LLC

Upgrade your Finviz experience